Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages
- PMID: 20422265
- DOI: 10.1007/s11095-010-0149-z
Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages
Abstract
Purpose: Cationic solid lipid nanoparticles (SLN) have established themselves during the past decades. They can efficiently bind DNA directly via ionic interaction and mediate gene transfection. One major problem with SLN is the lack of cell-targeting ability. In the present study, a mannan-based PE-grafted ligand was synthesized and used for the surface modification of DNA-loaded cationic SLN to prepare Man-SLN-DNA.
Methods: For in vitro test, the cytotoxicity and transfection investigation was carried out on murine macrophage cell line RAW 264.7. For in vivo evaluation, Man-SLN-DNA was delivered into the lung of the rats, and the alveolar macrophages (AM) were isolated for the fluorescence determination of transfection efficiency.
Results: When compared with non-modified SLN-DNA and Lipofectamine 2000-DNA, Man-SLN-DNA produced the highest gene expressions, especially in vivo.
Conclusion: These results demonstrated the active targeting ability of this kind of mannan-modified DNA-loaded vehicles, which may have great potential for targeted gene delivery.
Similar articles
-
Dual ligands modified double targeted nano-system for liver targeted gene delivery.Pharm Biol. 2013 May;51(5):643-9. doi: 10.3109/13880209.2012.761245. Epub 2013 Mar 26. Pharm Biol. 2013. PMID: 23527957
-
Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems.Int J Nanomedicine. 2012;7:2019-31. doi: 10.2147/IJN.S30928. Epub 2012 Apr 17. Int J Nanomedicine. 2012. PMID: 22619539 Free PMC article.
-
Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages.Eur J Pharm Sci. 2018 Mar 1;114:103-113. doi: 10.1016/j.ejps.2017.12.006. Epub 2017 Dec 8. Eur J Pharm Sci. 2018. PMID: 29229273
-
Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy.Int J Mol Med. 2014 Jul;34(1):191-6. doi: 10.3892/ijmm.2014.1770. Epub 2014 May 6. Int J Mol Med. 2014. PMID: 24804644
-
Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations.Drug Dev Ind Pharm. 2014 Dec;40(12):1565-75. doi: 10.3109/03639045.2014.909840. Epub 2014 Apr 25. Drug Dev Ind Pharm. 2014. PMID: 24766553 Review.
Cited by
-
Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.Pharmaceutics. 2023 Dec 29;16(1):61. doi: 10.3390/pharmaceutics16010061. Pharmaceutics. 2023. PMID: 38258072 Free PMC article. Review.
-
Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers.Drug Des Devel Ther. 2020 Jul 29;14:3057-3068. doi: 10.2147/DDDT.S256636. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32801644 Free PMC article.
-
Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer.Drug Des Devel Ther. 2020 Mar 12;14:1095-1105. doi: 10.2147/DDDT.S230306. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32210538 Free PMC article.
-
Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin.Mol Pharm. 2014 Dec 1;11(12):4425-36. doi: 10.1021/mp500565q. Epub 2014 Oct 27. Mol Pharm. 2014. PMID: 25314115 Free PMC article.
-
Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.Int J Nanomedicine. 2015 Feb 11;10:1223-33. doi: 10.2147/IJN.S77837. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25709444 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous